A Study of LY4065967 in Healthy Participants

Part of paid clinical trials in Daytona Beach, Florida.

Sponsor
Eli Lilly and Company
Study ID
NCT07607483
Phase
PHASE1
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Healthy

Eligibility Criteria

Sex
ALL
Age
18 Years - 55 Years
Healthy Volunteers
Accepted

Interventions

Study Details

The main purpose of this study is to compare 3 different forms of LY4065967 - a tablet and 2 types of capsule - to see how much and how quickly each gets into the bloodstream after it is swallowed, and to check for any side effects. For each participant, the study will last about 7 weeks and will include 3 stays in the Clinical Research Unit (CRU). Each stay will last 3 nights.

Key Dates

Start date
Jun 30, 2026
Status verified
May 2026
Primary completion
Jul 31, 2026
Completion
Jul 31, 2026

Study Design

Enrollment
36 participants (estimated)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: LY4065967 (Reference)
    Administered orally as a capsule in one of three treatment periods.
  • Experimental: LY4065967 (Test 1)
    Administered orally as a tablet in one of three treatment periods.
  • Experimental: LY4065967 (Test 2)
    Administered orally as a formulated capsule in one of three treatment periods.

Primary Outcome Measure

Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY4065967 [ Time Frame: Baseline Up to Day 17 ]

Central Contacts

  • Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
    1-317-615-4559
    [email protected]
  • Physicians interested in becoming principal investigators please contact
    [email protected]

Locations (2)

FacilityCityStateZIPSite coordinators
Fortrea Clinical Research UnitDaytona BeachFlorida32117
386-366-6400
Hugh Coleman (PRINCIPAL_INVESTIGATOR)
Fortrea Clinical Research UnitDallasTexas75247
214-647-9375
Gene Voskuhl (PRINCIPAL_INVESTIGATOR)

Find similar trials in Daytona Beach, FL

By research site
Fortrea Clinical Research Unit· Daytona Beach, FLFortrea Clinical Research Unit· Dallas, TX

Related Studies